ArticleJournal of pharmacy & bioallied sciences2025
Role of Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Clinical Diagnosed Alzheimer's Diseases.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the Core Role and Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease.Brain and behavior · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD), a neurodegenerative disorder closely associated with aging, is characterized by progressive cognitive decline and is a leading cause of dementia worldwide. Oxidative stress plays a pivotal role in AD's pathophysiology, contributing to amyloid-beta accumulation, neurofibrillary tangles, and neuronal damage. Aim: This study investigates the potential of F2-isoprostanes and Presenilin-1 (PSEN1) as biomarkers for oxidative stress and their association with clinically diagnosed Alzheimer's disease. Materials and Methods: A comparative cross-sectional study will be conducted, enrolling 50 AD patients and 50 age-matched healthy controls from the Vidarbha region. Serum levels of F2-isoprostanes and PSEN1 will be measured using advanced analytical techniques, and their correlation with AD progression will be analyzed statistically. Results and Conclusion: The findings are expected to provide insights into the diagnostic and prognostic value of these markers, offering potential avenues for early detection and therapeutic intervention in Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.